Skip to main content
Article thumbnail
Location of Repository

Fine tuning Exo2, a small molecule inhibitor of secretion and retrograde trafficking pathways in mammalian cells

By Lucie J. Guetzoyan, Robert A. Spooner, Frédéric Boal, David J. Stephens, Mike Lord, L. M. (Lynne M.) Roberts and Guy J. Clarkson


The small molecule 4-hydroxy-3-methoxybenzaldehyde (5,6,7,8-tetrahydro[1]benzothieno[2,3-\ud d]pyrimidin-4-yl)hydrazone (Exo2) stimulates morphological changes at the mammalian Golgi and\ud trans-Golgi network that are virtually indistinguishable from those induced by brefeldin A. Both\ud brefeldin A and Exo2 protect cells from intoxication by Shiga(-like) toxins by acting on other\ud targets that operate at the early endosome, but do so at the cost of high toxicity to target cells. The\ud advantage of Exo2 is that it is much more amenable to chemical modification and here we report a\ud range of Exo2 analogues produced by modifying the tetrahydrobenzothienopyrimidine core, the\ud vanillin moiety and the hydrazone bond that links these two. These compounds were examined for\ud the morphological changes they stimulated at the Golgi stack, the trans Golgi network and the\ud transferrin receptor-positive early endosomes and this activity correlated with their inherent\ud toxicity towards the protein manufacturing ability of the cell and their protective effect against\ud toxin challenge. We have developed derivatives that can separate organelle morphology, target\ud specificity, innate toxicity and toxin protection. Our results provide unique compounds with low\ud toxicity and enhanced specificity to unpick the complexity of membrane trafficking networks

Topics: QH
Publisher: Royal Society of Chemistry
Year: 2010
OAI identifier:

Suggested articles

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.